Carcinoma, Non-Small-Cell Lung
Conditions
Keywords
Lung Cancer, NSCLC, Cancer Vaccine, Stage IV Non-Small Cell Lung Cancer, Stage IIIb Non-Small Cell Lung Cancer with effusion
Brief summary
The primary Objective is to assess the efficacy of TG4010 combined to chemotherapy in comparison with chemotherapy alone in patients with advanced non small cell lung cancer.
Detailed description
In the experimental arm patients receive subcutaneous injections of TG4010 at the dose of 108 pfu in combination with chemotherapy treatment whereas patients in the control arm receive chemotherapy alone. The chemotherapy associates cisplatin and gemcitabine and is given for up to 6 cycles or progressive disease, whichever occurs first. TG4010 is administered once per week for 6 weeks, then once every 3 weeks in combination with chemotherapy and thereafter as monotherapy until documentation of progressive disease. Tumor response will be evaluated every 6 weeks by a CT-scan and results will be available before starting an additional treatment period of 6 weeks. The tumor response taken into account will be for each patient the best overall response obtained during the study. The endpoint of the study is based on Progression Free Survival (PFS) at 6 months.
Interventions
BIOLOGICALMVA-MUC1-IL2
MVA-MUC1-IL2: Dose of 10exp8 plaque forming units (pfu). Chemotherapy: Arm 1 and Arm 2 Intravenous CT: cisplatin (75mg/m² at Day 1) and gemcitabine (1250mg/m² at Days 1 and 8) every 3 weeks, for up to six cycles or until progressive disease, whichever occurred first.
DRUG1st line Chemotherapy
Sponsors
Transgene
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed non-small cell carcinoma of the lung (adenocarcinoma, squamous cell carcinoma, or large cell carcinoma); * Histological documentation of MUC1 antigen expression on the primary tumor or on metastasis, as defined by a positive staining by immuno-histo-chemistry in at least 25% of the tumor cells in the conditions described in the technical documentation of the monoclonal antibody; * Patients will have stage IIIb wet (with pleural or pericardial effusion) or IV disease, with no prior systemic therapy for advanced disease except for adjuvant treatment. Prior surgery or radiation therapy aimed at local palliation or attempted local disease control is permitted; * At least one measurable lesion by Computed Tomography (CT-scanner) according to WHO criteria (lesion accurately measured in two dimensions with longest diameter equal or greater to 10 mm with spiral CT scan); * Adequate hematological, hepatic, and renal function: * Hemoglobin \>= 10.0 g/dL; WBC \>= 3.0x10e9/L including neutrophils \>= 1.5x10e9/L and total lymphocytes count \>= 0.5x10e9/L; platelets count \>= 100x10e9/L; * Bilirubin =\< 2x the upper limit of normal and serum transaminases =\< 3x the upper limit of normal; * Glomerular Filtration Rate higher than 60 ml/mn according to Cockcroft formula; * Performance status 0 or 1 on the ECOG scale (Appendix 2); * Minimum estimated life expectancy of 4 months; * Written informed consent from patient.
Exclusion criteria
* Concomitant brain metastases. If previous brain metastases were treated, the absence of evolution is to be demonstrated by the MRI or scanner performed at baseline; * Prior history of other malignancy except basal cell carcinoma and intra-epithelial cervical cancer or other cancer with complete response since at least 5 years; * History of any form of systemic therapy for advanced non-small cell cancer of the lung except for (neo)adjuvant treatment; * Previous (within 4 weeks prior to day 1) or concomitant long term treatment with systemic steroids, immunosuppressive / immunomodulating drugs (e.g. Cyclosporine, corticoïds); * Positive serology for HIV or HCV; positive antigens for hepatitis B; * Serious concomitant medical disorder; * Major surgery within 4 weeks prior to day 1; * Patient with an organ allograft; * Allergy to eggs; * Participation in another experimental protocol during the study period, or within 4 weeks prior to day 1; * Pregnancy at the entry or women who are breast feeding; * Patient without adequate protection against pregnancy during the conduct of the study and for 3 months after the last injection of TG4010 and/or chemotherapy; * History of substance abuse; * Patient unable or unwilling to comply with the protocol requirements.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival at 6 months | 6 months |
Secondary
| Measure | Time frame |
|---|---|
| Response Rate according to WHO criteria | 6 months |
| Time to progression | 6 months |
| Overall survival | — |
| Quality of life | every 6 weeks |
Countries
France, Germany, Hungary, Poland
Outcome results
None listed